The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials

Table 2 Demographic and baseline clinical characteristics of the EPPIC-USA population (pooled ITT population)

	AST-120	Placebo	P-value
	N = 290	N = 293	P-value
Age, years, mean ± SD	60.1 ± 14.3	61.7 ± 12.3	0.15
Sex, %
Male	64.5	70.6	0.11
Race, %^a
White	66.6	60.8	0.51
Black or African American	19.7	25.3
Asian	6.2	5.1
Native Hawaiian or other Pacific Islander	0.7	0.7
American Indian or Alaska Native	0.0	0.3
Other	6.9	7.8
CKD etiology, %
Diabetic nephropathy	58.6	61.8	0.44
Type I Diabetes	6.2	3.4
Type II Diabetes	52.4	58.4
Non-diabetic nephropathy	41.4	38.2
Glomerulonephritis	7.6	12.3
Nephrosclerosis	16.2	15.7
Other	17.6	10.2
Use of ACEI or ARB, %
Yes	79.7	80.5	0.79
Baseline sCr, mg/dL, mean ± SD^b	3.01 ± 0.84	3.08 ± 0.80	0.28
Baseline eGFR, mL/min/1.73 m², mean ± SD	23.59 ± 7.79	23.04 ± 6.92	0.36
Baseline UP/UCr ratio
N	288	292	0.06
Mean ± SD	1.94 ± 1.29	2.15 ± 1.40
CKD stage, %
Stage 3a	0.3	0.7	0.70
Stage 3b	20.7	14.3
Stage 4	64.5	74.4
Stage 5	14.5	10.6
Baseline anemia status, %^c
Yes	76.2	79.9	0.25
BMI, kg/m^2d
N	289	293	0.20
Mean ± SD	31.8 ± 7.2	32.7 ± 8.7

^aRace was self-reported
^bTo convert sCr from mg/dL to mol/L, multiply by 88.4
^cAnemia was defined as a hemoglobin level <13.5 g/dL (men) or <12.0 g/dL (women)
^dBody mass index is the weight in kilograms divided by the square of the height in meters

ISSN: 1471-2369